Table 3 Baseline characteristics, induction therapy for kidney transplantation, and immunologic risk factors of the validation cohort.

From: Early postoperative urinary MCP-1 as a potential biomarker predicting acute rejection in living donor kidney transplantation: a prospective cohort study

 

Total (n = 79)

Control (n = 38)

AR (n = 41)

P value

Age, mean (SD) (years)

46.9 (11.2)

47.5 (10.7)

46.4 (11.7)

0.655

Male, number (%)

43 (54.4)

18 (47.4)

25 (70.0)

0.263

Cause of ESKD, number (%)

   

0.039

Diabetes mellitus

23 (29.1)

14 (36.8)

9 (22.0)

0.145

Hypertension

7 (8.9)

6 (15.8)

1 (2.4)

0.051

Glomerulonephritis

33 (41.7)

10 (26.4)

23 (56.1)

0.007

Others

7 (8.9)

4 (10.5)

3 (7.3)

0.705

Unknown

9 (11.4)

4 (10.5)

5 (12.2)

1.000

Induction therapy, number (%)

   

> 0.999

Basiliximab and steroid

43 (54.4)

19 (50.0)

24 (58.5)

 

ATG and steroid

12 (15.2)

7 (18.4)

5 (12.2)

 

Rituximab and steroid

24 (30.4)

12 (31.6)

12 (29.3)

 

ABO-incompatible KT, number (%)

15 (20.0)

9 (23.7)

6 (14.6)

0.393

PRA, class I (+), number (%)

19 (23.1)

9 (23.7)

10 (24.4)

> 0.999

% in patients with PRA, class I

 

32.3 ± 29.41

51.3 ± 29.60

 

PRA, class II (+), number (%)

14 (17.7)

6 (15.8)

8 (19.5)

0.772

% in patients with PRA, class II

 

29.7 ± 19.55

40.6 ± 31.21

 

DSA (+), number (%)

10 (12.7)

3 (7.9)

7 (17.1)

0.3145

  1. Continuous variables are expressed as mean (standard deviation) and categorical variables are expressed as number (percentage).
  2. Others for cause of ESKD included autosomal dominant polycystic kidney disease, lupus nephritis, obstructive nephropathy, and Alport syndrome.
  3. % in patients with PRA: mean ± standard deviation.
  4. AR acute rejection, ATG anti-thymocyte globulin, DSA donor specific antibodies, ESKD end-stage kidney disease, KT kidney transplantation, PRA panel reactive antibodies, SD standard deviation.
Back to article page